SCHEMBL2029352

SCHEMBL2029352

CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc4ocnc4c3)c(F)c2)ccn1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 11/20 0.74
MAPK14 Q16539 8/20 0.74
ABL1 P00519 3/20 0.74
RIPK1 Q13546 2/20 0.74
PLK4 O00444 1/20 0.74
ACOX3 O15254 1/20 0.74
MAP3K7 O43318 1/20 0.74
DYRK3 O43781 1/20 0.74
JAK2 O60674 1/20 0.74
ERN1 O75460 1/20 0.74
RPS6KA4 O75676 1/20 0.74
STK10 O94804 1/20 0.74
MAP4K4 O95819 1/20 0.74
RAF1 P04049 1/20 0.74
NTRK1 P04629 1/20 0.74
LCK P06239 1/20 0.74
FYN P06241 1/20 0.74
CDK1 P06493 1/20 0.74
FES P07332 1/20 0.74
CSF1R P07333 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2026902 0.90 MAPK14 (0.60) BRAFMAPK14ABL1RIPK1PLK4
SCHEMBL5062256 0.90 BRAF (0.76) BRAFMAPK14ABL1RIPK1PLK4
SCHEMBL12079695 0.89 BRAF (0.84) BRAFMAPK14ABL1RIPK1PLK4
Hydrochloric Acid SCHEMBL2029657 0.88 BRAF (0.83) BRAFMAPK14ABL1RIPK1PLK4
SCHEMBL2243266 0.88 BRAF (0.80) BRAFMAPK14ABL1RIPK1PLK4
SCHEMBL5054788 0.88 MAPK14 (0.70) BRAFMAPK14ABL1RIPK1PLK4
SCHEMBL2241121 0.87 BRAF (0.79) BRAFMAPK14ABL1RIPK1PLK4
SCHEMBL2242769 0.87 ABL1 (0.79) BRAFMAPK14ABL1RIPK1PLK4
SCHEMBL5060318 0.87 BRAF (0.76) BRAFMAPK14ABL1RIPK1PLK4
SCHEMBL2243259 0.87 ABL1 (0.78) BRAFMAPK14ABL1RIPK1PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed
EP-2073811-B1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS LLC (US) 2015-03-11 EP disclosed
US-8586565-B2 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2013-11-19 US disclosed
WO-2013036232-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-03-14 WO disclosed
US-20120225057-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-09-06 US disclosed
US-20110136760-A1 Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases DECIPHERA PHARMACEUTICALS, LLC 2011-06-09 US disclosed
US-7790756-B2 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2010-09-07 US disclosed
EP-2073811-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-07-01 EP disclosed
WO-2008046003-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-04-17 WO disclosed
US-20080090856-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225057-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES ABL1, MCL1, ABL2 BRAF 5/4885MAPK14 323/4885ABL1 1/4885
US-20080090856-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES MYLK3, MYLK, CDK3 BRAF 115/4885MAPK14 354/4885ABL1 81/4885
US-20110136760-A1 Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases MYLK3, MYLK, CDK3 BRAF 115/4885MAPK14 354/4885ABL1 81/4885
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 BRAF 2/4885MAPK14 100/4885ABL1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.